Table 4 Association of tumor PD-L1 and B7-H3 expression with clinicopathological features
Feature | Tumor PD-L1 expression | P* | Tumor B7-H3 expression | P* | ||
|---|---|---|---|---|---|---|
High (n = 8) | Low/negative (n = 73) | High (n = 17) | Low/negative (n = 64) | |||
Age | 0.932 | 0.818 | ||||
Mean (SD) | 61 (7.1) | 61.3 (9.9) | 61.4 (7.7) | 60.8 (10.5) | ||
Median | 61.9 | 61.6 | 60.6 | 62.7 | ||
Gender | 0.677 | 0.345 | ||||
Male | 7 (87.5%) | 56 (76.7%) | 15 (88.2%) | 49 (76.6%) | ||
Female | 1 (12.5%) | 17 (23.3%) | 2 (11.8%) | 15 (23.4%) | ||
Tumor stage | 0.424 | 0.242 | ||||
≤ T2b | 1 (87.5%) | 24 (32.9%) | 3 (17.6%) | 22 (34.4%) | ||
≥ T3a | 7 (12.5%) | 49 (67.1%) | 14 (82.4%) | 42 (65.6%) | ||
LN status | 0.084 | 0.351 | ||||
Positive | 5 (62.5%) | 63 (86.3%) | 13 (76.5%) | 55 (85.9%) | ||
Negative | 3 (37.5%) | 10 (13.7%) | 4 (23.5%) | 9 (14.1%) | ||
Histological type | 0.352 | 0.054 | ||||
Pure UC | 8 (100%) | 61 (83.7%) | 17 (100%) | 52 (81.3%) | ||
Other subtypes | 0 (0%) | 12 (16.4%) | 0 (0%) | 12 (18.7%) | ||